Moderna has produced the first batch of a vaccine against the South African strain of coronavirus

Clinical trials of the modified vaccine may begin within a few weeks.

The pharmaceutical company Moderna said it produced the first batch of doses of a new vaccine with increased efficacy against a new strain of coronavirus that proved more resistant to the company’s original vaccine.

The Cambridge, Massachusetts-based company said it sent doses of the new vaccine to the National Institutes of Health to conduct the first human trial of the modified vaccine. It can start within a few weeks.

The new vaccine, codenamed mRNA-1273.351, is designed to provide a higher degree of protection against a variant of the virus that was first detected in South Africa but has since spread to other countries.

Other companies, including Pfizer and Johnson & Johnson, have said they are also modifying their vaccines or working on boosters that better match the new variants of the virus.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Author: Ivan Maltsev
The study of political and social problems of different countries of the world. Analysis of large companies on the world market. Observing world leaders in the political arena.
Function: Chief-Editor
Ivan Maltsev

Spelling error report

The following text will be sent to our editors: